



## Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

## CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission

Dec 1 2021, 8:00 AM EST

## CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow

Nov 29 2021, 4:27 PM EST

## CytoDyn Announces Preliminary Results from 2021 Annual Meeting

Nov 24 2021, 4:01 PM EST

## Management Team

### Nader Z. Pourhassan, Ph.D.

Director, President and CEO

### Scott A. Kelly, M.D.

Chief Medical Officer, Head of Business Development and Chairman of the Board

### Nitya G. Ray, Ph.D.

Chief Operating Officer and Chief Technology Officer

### Christopher Recknor, M.D.

Senior Executive VP of Clinical Operations

### Antonio Migliarese, C.P.A.

Chief Financial Officer

---

## CytoDyn Inc.

1111 Main Street  
Suite 660  
Vancouver, WA 98660

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.